TY - JOUR ID - 250382 TI - Upregulation of CD4+T-Cell Derived MiR-223 in The Relapsing Phase of Multiple Sclerosis Patients JO - Cell Journal (Yakhteh) JA - CELLJ LA - en SN - 2228-5806 AU - Hosseini, Aref AU - Ghaedi, Kamran AU - Tanhaei, Somayeh AU - Ganjalikhani-Hakemi, Mazdak AU - Teimuri, Shohreh AU - Etemadifar, Masoud AD - Division of Cellular and Molecular Biology, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran AD - Division of Cellular and Molecular Biology, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran;Department of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotech AD - Department of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran AD - Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran AD - 4Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Y1 - 2016 PY - 2016 VL - 18 IS - 3 SP - 371 EP - 380 KW - CD4+T KW - Cell KW - MicroRNAs KW - MiR KW - 223 KW - multiple sclerosis KW - Th17 DO - 10.22074/cellj.2016.4565 N2 - ObjectiveMicroRNAs (miRNA) are a class of non-coding RNAs which play key roles in post-transcriptional gene regulation. Previous studies indicate that miRNAs are dysregulated in patients with multiple sclerosis (MS). Th17 and regulatory T (Treg) cells are two subsets of CD4+T-cells which have critical functions in the onset and progression of MS. The current study seeks to distinguish fluctuations in expression of CD4+T-cell derived miR-223 during the relapsing-remitting (RR) phase of MS (RR-MS), as well as the expressions of Th17 and Treg cell markers. Materials and MethodsThis experimental study used real-time quantitative polymerase chain reaction (qRT-PCR) to evaluate CD4+ T cell derived miR-223 expression patterns in patients that experienced either of the RR-MS phases (n=40) compared to healthy controls (n=12), along with RNA markers for Th17 and Treg cells. We conducted flow cytometry analyses of forkhead box P3 (FOXP3) and RAR-related orphan receptor γt (RORγt) in CD4+T-cells. Putative and validated targets of miR-223 were investigated in the miRWalk and miRTarBase databases, respectively. ResultsmiR-223 significantly upregulated in CD4+T-cells during the relapsing phase of RR-MS compared to the remitting phase (P=0.000) and healthy individuals (P=0.036). Expression of RORγt, a master transcription factor of Th17, upregulated in the relapsing phase, whereas FOXP3 upregulated in the remitting phase. Additionally, potential targets of miR-223, STAT1, FORKHEAD BOX O (FOXO1) and FOXO3 were predicted by in silico studies. ConclusionmiR-223 may have a potential role in MS progression. Therefore, suppression of miR-223 can be proposed as an appropriate approach to control progression of the relapsing phase of MS. UR - https://www.celljournal.org/article_250382.html L1 - https://www.celljournal.org/article_250382_df6dd08959b833aa2adf3276ff8155c1.pdf ER -